Maitreya Medica.

Who are the top shareholders of the Maitreya?

The top shareholder of Maitreya is Narendra Singh Tanwar, holding 47.02%. Individual investors own 22.01%, with South Gujarat Shares And Sharebrokers Limited as the largest public shareholder at 2.27%, and a foreign institutional investor holding 0.01%.

The top shareholders of Maitreya include the promoters, with Narendra Singh Tanwar holding the largest share at 47.02%. There are no pledged promoter holdings, and individual investors collectively own 22.01% of the company. The highest public shareholder is South Gujarat Shares And Sharebrokers Limited, which holds 2.27%. Additionally, there is one foreign institutional investor (FII) that holds a very small stake of 0.01%.

how big is Maitreya?

As of October 2023, Maitreya Medicare Ltd has a market capitalization of 195.00 Cr, with recent net sales of 49.48 Cr and a net profit of 4.94 Cr over the last four quarters. Shareholder's funds are 14.51 Cr, and total assets are 28.91 Cr as of March 2023.

Market Cap: Maitreya Medicare Ltd has a market capitalization of 195.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which is consolidated data, amounts to 49.48 Cr. The sum of Net Profit for the same period is 4.94 Cr.<BR><BR>Balance Sheet Snapshot: This is consolidated data for the latest annual period ending in March 2023. Shareholder's Funds are reported at 14.51 Cr, while Total Assets stand at 28.91 Cr.

What does Maitreya do?

Maitreya Medicare Ltd is a micro-cap company in the hospital industry, incorporated in 2019 and renamed in 2023. As of March 2024, it reported net sales of 12 Cr and a net profit of -1 Cr, with a market cap of Rs 195 Cr.

Overview:<BR>Maitreya Medicare Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated as Maitreya Medicare Private Limited in 2019. It underwent a name change to Maitreya Medicare Limited, with the new name officially registered on March 30, 2023. The most recent quarterly results reported net sales and net profit for the period ending March 2024.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 12 Cr (Quarterly Results - Mar 2024) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2024) <BR>Market-cap value: Rs 195 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 97.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.09 <BR>Return on Equity: 6.28% <BR>Price to Book: 6.08 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are in the management team of Maitreya?

As of March 2023, the management team of Maitreya includes Narendra Singh Tanwar (Managing Director & CFO), Pranav Rohitbhai Thaker and Vimalkumar Natverlal Patel (Whole-time Directors), Hardik Patel and Abha Surana (Independent Directors), and Payal Mathur (Company Secretary & Compliance Officer).

As of March 2023, the management team of Maitreya includes:<BR><BR>1. Narendra Singh Tanwar - Managing Director & CFO<BR>2. Pranav Rohitbhai Thaker - Whole-time Director<BR>3. Vimalkumar Natverlal Patel - Whole-time Director<BR>4. Hardik Patel - Independent Director<BR>5. Abha Surana - Independent Director<BR>6. Payal Mathur - Company Secretary & Compliance Officer<BR><BR>These individuals play key roles in the governance and operational management of the company.

When is the next results date for Maitreya?

No Upcoming Board Meetings

Has Maitreya declared dividend?

No Dividend History Available

Who are the peers of the Maitreya?

Maitreya's peers include Max Healthcare, Apollo Hospitals, Fortis Health, and others, with varying management risks and growth rates. Fortis Health has the highest 1-year return at 59.53%, while Maitreya and KHFM Hospitality both have a 0.00% return.

Peers: The peers of Maitreya are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Lotus Eye Hospit, Fortis Malar, KHFM Hospitality, Vaidya Sane, and Sangani Hospital.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, while Average management risk is found at Fortis Health., Lotus Eye Hospit, and the rest. Growth is Excellent at Max Healthcare and Apollo Hospitals, Good at Narayana Hrudaya and Fortis Health., while Below Average growth is noted at Fortis Malar, KHFM Hospitality, and the rest. Capital Structure is Excellent at Max Healthcare and Global Health, Good at Fortis Health., Narayana Hrudaya, Vaidya Sane, and the rest, while Below Average is seen at Fortis Malar, KHFM Hospitality, and Sangani Hospital.<BR><BR>Return Snapshot: Fortis Health. has the highest 1-year return at 59.53%, while KHFM Hospitality has the lowest at 0.00%. Maitreya's 1-year return is also 0.00%, which is lower than Fortis Health.'s return. Additionally, Global Health and Lotus Eye Hospit have negative six-month returns.

What is the technical trend for Maitreya?

As of June 6, 2025, Maitreya's technical trend is mildly bearish, indicated by a bearish weekly MACD, daily moving averages, and OBV, despite a mildly bullish KST signal.

As of 6 June 2025, the technical trend for Maitreya has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the daily moving averages also indicate a bearish stance. The KST shows a mildly bullish signal, but this is countered by the Dow Theory, which is mildly bearish on a weekly basis. The OBV is also mildly bearish, suggesting selling pressure. Overall, the current technical stance is mildly bearish, with key indicators such as the weekly MACD and daily moving averages driving this outlook.

Is Maitreya Medica. overvalued or undervalued?

As of August 28, 2025, Maitreya Medica's valuation has improved to attractive, indicating it is undervalued compared to peers like Apollo Hospitals and Max Healthcare, with a PE ratio of 94.15, an EV to EBITDA of 36.98, and a ROCE of 10.49%, while also outperforming the Sensex with a 1-week stock return of 3.55%.

As of 28 August 2025, Maitreya Medica's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 94.15, an EV to EBITDA of 36.98, and a ROCE of 10.49%. <BR><BR>In comparison with peers, Apollo Hospitals, which is also rated attractive, has a significantly lower PE ratio of 70.56, while Max Healthcare is deemed very expensive with a PE of 93.61. This suggests that Maitreya Medica may offer better value relative to its earnings potential. Notably, Maitreya Medica has outperformed the Sensex in the short term, with a 1-week stock return of 3.55% compared to a -2.32% return for the index.

How has been the historical performance of Maitreya Medica.?

Maitreya Medica's historical performance has shown fluctuations, with net sales declining from 49.41 Cr in Mar'22 to 46.66 Cr in Mar'25, and profits decreasing significantly, while total assets and liabilities increased from 24.49 Cr to 47.99 Cr during the same period. Cash flow improved to 5.00 Cr in Mar'25 after a negative cash flow in Mar'24.

Answer:<BR>The historical performance of Maitreya Medica shows fluctuations in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Maitreya Medica's net sales decreased from 49.41 Cr in Mar'22 to 46.66 Cr in Mar'25, with a notable dip in Mar'24 at 47.80 Cr and a low of 39.38 Cr in Mar'23. Total operating income followed a similar trend, peaking in Mar'22 and declining to 46.66 Cr by Mar'25. The total expenditure, excluding depreciation, decreased from 46.05 Cr in Mar'22 to 41.80 Cr in Mar'25, which contributed to an operating profit (PBDIT) of 5.45 Cr in Mar'25, down from 7.82 Cr in Mar'23. Profit before tax also saw a decline, dropping from 5.93 Cr in Mar'23 to 3.21 Cr in Mar'25, while profit after tax fell from 4.25 Cr in Mar'23 to 1.87 Cr in Mar'25. The earnings per share (EPS) decreased from 8.57 in Mar'23 to 2.76 in Mar'25. On the balance sheet, total assets increased from 24.49 Cr in Mar'22 to 47.99 Cr in Mar'25, while total liabilities rose from 24.49 Cr to 47.99 Cr in the same period. Cash flow from operating activities improved to 5.00 Cr in Mar'25, contrasting with a negative cash flow of -2.00 Cr in Mar'24. Overall, Maitreya Medica has experienced a mixed performance with fluctuations in sales, profits, and cash flow, alongside a significant increase in total assets and liabilities.

Should I buy, sell or hold Maitreya Medica.?

Why is Maitreya Medicare Ltd falling/rising?

As of 18-Jan, Maitreya Medicare Ltd's stock price is at 214.15, reflecting a decline of 1.72% and a significant drop of 35.50% over the past year. The company's weak fundamentals, lack of recent financial disclosures, and poor profitability metrics contribute to a negative outlook, labeling the stock as a strong sell.

As of 18-Jan, Maitreya Medicare Ltd's stock price is falling, currently at 214.15, which reflects a decrease of 3.75 or 1.72%. The stock has underperformed its sector by 0.76% today and has shown a significant decline over the past year, with a return of -35.50%. This poor performance is compounded by the company's weak long-term fundamentals, as it has not declared results in the last six months, indicating a lack of transparency and potential financial instability.<BR><BR>The company's profitability is also concerning, with a Return on Equity averaging only 8.20%, and recent financial results showing a substantial loss, with a Profit After Tax of -0.89 crore, which has fallen by 166.8%. Additionally, the Operating Profit to Net Sales ratio is at its lowest, recorded at -7.74%. These factors contribute to the perception of the stock as a strong sell, as it has consistently underperformed compared to benchmarks like the Sensex, which has gained 10.22% over the same period.<BR><BR>Despite a slight increase in investor participation, with a 25% rise in delivery volume, the overall outlook remains negative due to the company's declining profits and lack of recent financial disclosures. The stock's current trading levels are also risky compared to its historical valuations, further supporting the downward trend in its price.

Which are the latest news on Maitreya Medica.?